KR20210123309A - Crispr 활성을 조절하는 시스템 및 방법 - Google Patents

Crispr 활성을 조절하는 시스템 및 방법 Download PDF

Info

Publication number
KR20210123309A
KR20210123309A KR1020217023538A KR20217023538A KR20210123309A KR 20210123309 A KR20210123309 A KR 20210123309A KR 1020217023538 A KR1020217023538 A KR 1020217023538A KR 20217023538 A KR20217023538 A KR 20217023538A KR 20210123309 A KR20210123309 A KR 20210123309A
Authority
KR
South Korea
Prior art keywords
polynucleotide
crispr
nucleotide
cleavable linker
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217023538A
Other languages
English (en)
Korean (ko)
Inventor
리드 켈소
자레드 칼슨-스티버머
사힐 조시
트라비스 마우레스
아나스타시아 카디나
죤 앤드류 워커
Original Assignee
신테고 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신테고 코포레이션 filed Critical 신테고 코포레이션
Publication of KR20210123309A publication Critical patent/KR20210123309A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217023538A 2019-01-25 2020-01-25 Crispr 활성을 조절하는 시스템 및 방법 Abandoned KR20210123309A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797122P 2019-01-25 2019-01-25
US62/797,122 2019-01-25
US201962876177P 2019-07-19 2019-07-19
US62/876,177 2019-07-19
US201962939553P 2019-11-22 2019-11-22
US62/939,553 2019-11-22
PCT/US2020/015127 WO2020154714A2 (en) 2019-01-25 2020-01-25 Systems and methods for modulating crispr activity

Publications (1)

Publication Number Publication Date
KR20210123309A true KR20210123309A (ko) 2021-10-13

Family

ID=71735803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217023538A Abandoned KR20210123309A (ko) 2019-01-25 2020-01-25 Crispr 활성을 조절하는 시스템 및 방법

Country Status (9)

Country Link
US (2) US11884918B2 (https=)
EP (1) EP3914714A4 (https=)
JP (1) JP2022523055A (https=)
KR (1) KR20210123309A (https=)
CN (1) CN113874503A (https=)
AU (1) AU2020210884A1 (https=)
CA (1) CA3127486A1 (https=)
GB (1) GB2597377A (https=)
WO (1) WO2020154714A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US20220411790A1 (en) * 2019-10-25 2022-12-29 The Johns Hopkins University A crispr-cas9 platform with an intrinsic off-switch and enhanced specificity
US20240200059A1 (en) * 2021-04-09 2024-06-20 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
CN114410752B (zh) * 2022-01-24 2024-06-25 华南师范大学 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法
US20260103702A1 (en) * 2022-09-30 2026-04-16 Board Of Trustees Of Southern Illinois University Compositions and methods for crispr modulation
WO2024215715A2 (en) * 2023-04-11 2024-10-17 President And Fellows Of Harvard College Chemical ligation techniques

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US20090181858A1 (en) * 2004-09-21 2009-07-16 The Scripps Research Institute Adding photoregulated amino acids to the genetic code
BRPI0617191A2 (pt) * 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US7923562B2 (en) 2008-06-16 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Photocleavable linker methods and compositions
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011107747A2 (en) * 2010-03-05 2011-09-09 Medical Research Council Genetically encoded photocontrol
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2013065827A1 (ja) * 2011-11-04 2013-05-10 国立大学法人埼玉大学 核酸リンカー
US9228207B2 (en) * 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10093929B2 (en) * 2013-10-14 2018-10-09 Stc.Unm Modular RNA regulators and methods
US20150376586A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
WO2016022866A1 (en) 2014-08-07 2016-02-11 Agilent Technologies, Inc. Cis-blocked guide rna
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
WO2016094874A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
US9650617B2 (en) * 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
JP2018515142A (ja) * 2015-05-15 2018-06-14 ダーマコン，インコーポレイテッド． Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ
EP3353309A4 (en) * 2015-09-25 2019-04-10 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHOD FOR GENERIC EDITING
CN109072224B (zh) * 2016-01-30 2022-07-15 株式会社博纳克 人工单导rna及其用途
US20200291369A1 (en) 2016-03-11 2020-09-17 Erasmus University Medical Center Rotterdam Improved CRISPR-Cas9 Genome Editing Tool
EP3219799A1 (en) * 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
CN109415729B (zh) 2016-04-21 2022-12-09 生命技术公司 具有降低毒性的基因编辑试剂
WO2017217768A1 (ko) * 2016-06-15 2017-12-21 주식회사 툴젠 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도
EP3638789A4 (en) * 2017-06-12 2021-03-10 California Institute of Technology CONDITIONAL GUIDE RNAS

Also Published As

Publication number Publication date
CA3127486A1 (en) 2020-07-30
US20240209356A1 (en) 2024-06-27
JP2022523055A (ja) 2022-04-21
EP3914714A2 (en) 2021-12-01
CN113874503A (zh) 2021-12-31
WO2020154714A2 (en) 2020-07-30
US11884918B2 (en) 2024-01-30
GB2597377A (en) 2022-01-26
AU2020210884A1 (en) 2021-08-12
EP3914714A4 (en) 2024-04-10
US20220073912A1 (en) 2022-03-10
GB202110534D0 (en) 2021-09-08
WO2020154714A3 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
US11884918B2 (en) Systems and methods for modulating CRISPR activity
CN112585268B (zh) 通过插入供体多核苷酸用于基因组编辑的组合物和方法
ES2884838T3 (es) ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS
US12139707B2 (en) Stabilized CRISPR complexes
AU2018338967B2 (en) In vitro method of mRNA delivery using lipid nanoparticles
KR102438360B1 (ko) 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
JP2024116119A (ja) 改変ｃｐｆ１ガイドｒｎａ
CN115484932A (zh) 用于靶向rna递送的组合物和方法
TW202317764A (zh) 用於基因編輯之包含內部連接子之經修飾引導rna
JP2024534945A (ja) 化学修飾を有するプライム編集のためのガイドｒｎａ
JP2017046710A (ja) 遺伝子療法適用のためのスーパーコイル状ミニサークルｄｎａ
JP2024533448A (ja) 化学修飾を有するガイドｒｎａを使用する方法
Tou et al. Immune evasive DNA donors and recombinases license kilobase-scale writing
US20250302925A1 (en) Conjugated crispr-cas complexes
HK40060726A (en) Systems and methods for modulating crispr activity
HK40060724A (en) Stabilized crispr complexes
WO2025061842A1 (en) Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
WO2024220715A2 (en) Effector proteins and uses thereof
HK40061440A (zh) 用於抑制乙型肝炎病毒的基因表达的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1902 Submission of document of abandonment before decision of registration